Heterologous fibrin sealant derived from snake venom: from bench to bedside - an overview
J. venom. anim. toxins incl. trop. dis
;
23: 21, 2017. tab, graf, ilus
Artigo
em Inglês
| LILACS, VETINDEX
| ID: biblio-954833
ABSTRACT
Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.(AU)
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Venenos de Serpentes
/
Fibrinogênio
/
Adesivo Tecidual de Fibrina
/
Serina Proteases
Limite:
Animais
Idioma:
Inglês
Revista:
J. venom. anim. toxins incl. trop. dis
Ano de publicação:
2017
Tipo de documento:
Artigo
Instituição/País de afiliação:
São Paulo State University/BR
Similares
MEDLINE
...
LILACS
LIS